Category: Insights

How Pharmacists Are Trapped in the Middle of Drug Price Wars

Pharmacists, as the interface between the general public and prescription drug manufacturers, can sometimes feel as if they’re treading a fine line between fulfilling their obligations to pharmaceutical companies and…
The post How Pharmacists Are Trapp…


How to Use Tentative Drug Approvals to Anticipate Generic Entry

Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies will be first to launch generic drugs. Payers need to…
The post How to Use Tentative Drug Approvals to Anticipate Generic Entry appeared first …


How to Use Tentative Drug Approvals to Anticipate Generic Entry

Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies will be first to launch generic drugs. Payers need to…
The post How to Use Tentative Drug Approvals to Anticipate Generic Entry appeared first …


Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study

This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…


Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

This paper was originally published by Martin Schiestl, Markus Zabransky, and Fritz Sörgel in Drug Des Devel Ther. 2017; 11: 1509–1515 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract…
The post Ten years of biosi…


Make better decisions with advanced biopharmaceutical business intelligence

What can we build for you? Do you have special business intelligence needs? Let us apply our industry expertise and the strength of the DrugPatentWatch platform to develop a solution…
The post Make better decisions with advanced biopharmaceutical busin…


Driving Innovation: Drug Patents vs. Prizes

Joseph E Stiglitz, American economist and professor at Columbia University, states that prizes should be favored over patents to reward and stimulate innovation. The uniqueness of the patent system referred…
The post Driving Innovation: Drug Patents vs…


Review of Drug Repositioning Approaches and Resources

This paper was originally published by Hanqing Xue, Jie Li, Haozhe Xie, and Yadong Wang in Int J Biol Sci 2018; 14(10):1232-1244 under a Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). Abstract Drug…
T…


Measuring the effectiveness and impact of an open innovation platform

This paper was originally published by Glenn P. Carroll, Sanjay Srivastava, Adam S. Volini, Marta M. Piñeiro-Núñez, and TatianaVetman in Drug Discovery Today Volume 22, Issue 5, May 2017, Pages 776-785 under…
The post Measuring the effectiveness and im…


Viagra: A Complicated Case Study of Generic Drug Market Entry in the United States

The story of Viagra’s patents and generic entry of sildenafil citrate is a valuable one because it covers many of the nuances of drug patenting and generic entry in the…
The post Viagra: A Complicated Case Study of Generic Drug Market Entry in the Unit…


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: